The Association among Antioxidant Enzymes, Autoantibodies, and Disease Severity Score in Systemic Lupus Erythematosus: Comparison of Neuropsychiatric and Nonneuropsychiatric Groups
Table 1
Baseline characteristics of the SLE patients and control subjects.
SLE
Controlγ
P valueα,β,γ
NPSLEα, n = 15
Non-NPSLEβ, n = 17
n = 16
Age
44.8 ± 12.6
38.2 ± 11.8
46.1 ± 12.2
0.159
Sex
0.992
Female
13
15
14
Male
2
2
2
Presented with median (IQR)
White blood cell
6700 (4900.00, 9500.00)
5500 (4500.00, 6850.00)
5500 (4425.00, 6000.00)
0.44
Granulocyte (%)
70 (59.00, 82.80)
68.6 (60.98, 80.23)
55.9 (52.00, 68.20)
0.20
Lymphocyte (%)
24 (11.60, 26.70)
22.85 (12.03, 30.73)
34.8 (24.30, 39.00)
0.10
Monocyte (%)
5.5 (3.45, 10.10)
5.45 (4.03, 7.15)
5.9 (4.60, 6.80)
0.72
Hemoglobulin
11.9 (10.90, 13.20)
12.15 (9.90, 13.28)
13.45 (12.33, 14.10)
0.10
Platelet
216 (105.00, 251.00)
235.5 (171.75, 338.00)
205.5 (180.75, 256.00)
0.71
ESR
31 (11.00, 42.00)
18 (9.25, 36.75)
12 (10.00, 1.007)
0.38
CRP
1.6 (0.52, 17.10)
4.97 (0.99, 13.33)
0.57 (0.43, 1.27)
0.034*
Creatinine
0.63 (0.51, 0.86)
0.68 (0.54, 0.84)
ND
0.73
a-dsDNA
56.4 (15.00, 199.58)
34.95 (2.50, 163.00)
ND
0.51
a-ro
0.5 (0.10, 56.00)
0.3 (0.00, 300.00)
ND
0.25
a-la
0.1 (0.00, 0.75)
0 (0.00, 300.00)
ND
0.02*
p-ANCA
0 (0.00, 0.00)
0 (0.00, 0.10)
ND
0.18
c-ANCA
0 (0.00, 0.10)
0.1 (0.00, 0.10)
ND
0.10
a-U1RNP
0.8 (0.10, 1.20)
3.65 (1.25, 84.75)
ND
0.08
a-sm
0.1 (0.01, 0.30)
0.65 (0.20, 2.90)
ND
0.29
a-rib p
0.2 (0.10, 0.50)
0.7 (0.50, 55.00)
ND
0.37
a-ro60
0.9 (0.00, 98.00)
0.2 (0.1, 300.00)
ND
0.30
a-β2GP1
0.01 (0.01, 0.8)
2.8 (0.01, 14)
ND
0.06
a-Cardiolipin G
2.3 (0.83, 11)
7.2 (1.4, 46)
ND
0.37
a-Cardiolipin M
0.01 (0.01, 0.45)
0.01 (0.01, 0.21)
ND
0.88
Glutathione
1.44 (1.14, 1.67)
1.2 (0.90, 1.50)
1.14 (1.01, 1.29)
0.08
SOD-rbc
1770.94 (1349.83, 1957.72)
1409.97 (1250.2, 1519.54)
2983.7 (2204.70, 3281.10)
<0.001*
GPX-rbc
51.99 (39.20, 73.90)
52.62 (36.16, 74.06)
57.1 (46.10, 66.40)
0.48
SLE, systemic lupus erythematosus; NP, neuropsychiatric; ESR, erythrocyte sediment rate; CRP, c-reactive protein; a-dsDNA, antidouble strand DNA; a-ro, anti-Ro52/60 kDa; a-la, anti-La; p-ANCA, perinuclear anti-neutrophil cytoplasmic antibodies; c-ANCA, cytoplasmic anti-neutrophil cytoplasmic antibodies; anti-U1 ribonucleoprotein; a-sm, anti-Smith; anti-rib p, antiribosomal p; a-ro60, anti-Ro 60 kDa; a-2GP1, anti-2 glycoprotein I; a-cardiolipin G, a-cardiolipin IgG; acardiolipin M, a-cardiolipin IgM; SOD-rbc, superoxide dismutase; GPX-rbc, glutathione peroxidase;. IQR, inter-quartile range. Patients with () or without () neuropsychiatric symptoms or signs related to SLE disease activity. Normal control group. P value was acquired by using one-way ANOVA-Bonferroni test. Indicates P < 0.05.
